Cardium Announces Participation in Upcoming Investor Conferences.SAN DIEGO San Diego (săn dēā`gō), city (1990 pop. 1,110,549), seat of San Diego co., S Calif., on San Diego Bay; inc. 1850. San Diego includes the unincorporated communities of La Jolla and Spring Valley. Coronado is across the bay. -- Cardium Therapeutics, Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :CDTP CDTP Cold Differential Test Pressure CDTP Computer Technology Documentation Project ) announced today that Cardium's Chairman and Chief Executive Officer, Christopher J. Reinhard, will present at the following upcoming investor conferences: * Saturday, May 19, 2007 at 10:00 a.m. PT at the San Diego Growth Conference at the Hilton La Jolla Torrey Pines, La Jolla, CA * Tuesday, May 22, 2007 at 11:10 a.m. ET at the Wall Street Analyst Forum at the Princeton Club, New York New York, state, United States New York, Middle Atlantic state of the United States. It is bordered by Vermont, Massachusetts, Connecticut, and the Atlantic Ocean (E), New Jersey and Pennsylvania (S), Lakes Erie and Ontario and the Canadian province of , NY * Thursday, May 24, 2007 at 10:40 a.m. ET at the Friedland Undervalued Undervalued A stock or other security that is trading below its true value. Notes: The difficulty is knowing what the "true" value actually is. Analysts will usually recommend an undervalued stock with a strong buy rating. Equities Conference at the Doubletree Metropolitan Hotel, New York, NY * Tuesday, May 29, 2007 at 11:00 a.m. PT at the RedChip Small-Cap Investor Conference at the Ritz Carleton, San Francisco, CA A live and archived webcast of each conference presentation, as well as a copy of the presentation to be used at the conferences, will be available on the Investor Relations Investor relations The process by which the corporation communicates with its investors. section of www.cardiumthx.com. About Cardium Cardium Therapeutics, Inc. and its subsidiaries, InnerCool Therapies, Inc. and the Tissue Repair Company, are medical technology companies primarily focused on the development, manufacture and sale of innovative therapeutic products and devices for cardiovascular, ischemic Ischemic An inadequate supply of blood to a part of the body, caused by partial or total blockage of an artery. Mentioned in: Antiangiogenic Therapy, Subarachnoid Hemorrhage, Ventricular Fibrillation ischemic and related indications. Cardium's lead product candidate, Generx (alferminogene tadenovec, Ad5FGF-4), is a DNA-based growth factor therapeutic being developed for potential use by interventional cardiologists as a one-time treatment to promote and stimulate the growth of collateral circulation collateral circulation n. Circulation maintained in small anastomosing vessels when the main artery is obstructed. collateral circulation in the hearts of patients with ischemic conditions such as recurrent angina recurrent angina Cardiology Sharp precordial pain directly related to cardiac ischemia, seen in 3-5% of Pts with CABG, due either to progressive stenosis or occlusion of a CABG or progressive stenosis in an ungrafted artery. See Angina, CABG, Triple-bypass surgery. . For more information about Cardium Therapeutics and its businesses, products and therapeutic candidates, please visit www.cardiumthx.com or view its recent 2006 Annual Report at www.cardiumthx.com/flash/pdf/2006CardiumAnnualReport.pdf. Cardium's InnerCool Therapies subsidiary is a San Diego-based medical technology company in the emerging field of temperature modulation therapy to rapidly and controllably cool the body in order to reduce cell death and damage following acute ischemic events such as cardiac arrest cardiac arrest n. Abbr. CA A sudden cessation of cardiac function, resulting in loss of effective circulation. Cardiac arrest A condition in which the heart stops functioning. or stroke, and to potentially lessen or prevent associated injuries such as adverse neurological outcomes. For more information about Cardium's InnerCool subsidiary and therapeutic hypothermia hypothermia Abnormally low body temperature, with slowing of physiological activity. It is artificially induced (usually with ice baths) for certain surgical procedures and cancer treatments. , including InnerCool's Celsius Control System[TM], which has received regulatory clearance in the U.S., Europe and Australia, please visit www.innercool.com. Cardium's Tissue Repair Company subsidiary (TRC TRC Noun (in South Africa) Truth and Reconciliation Commission: a commission which encourages people who committed human rights abuses or acts of terror during the apartheid era to reveal the truth about their crimes in return for immunity from prosecution ) is a San Diego-based biopharmaceutical company focused on the development of growth factor therapeutics for the treatment of severe chronic diabetic wounds. TRC's lead product candidate, Excellarate[TM], is a DNA-activated collagen gel for topical treatment formulated with an adenovector delivery carrier encoding human platelet-derived growth factor-BB (PDGF-BB). Excellarate[TM] is initially being developed to be administered once or twice for the potential treatment of non-healing diabetic foot diabetic foot A foot with a constellation of pathologic changes affecting the lower extremity in diabetics, often leading to amputation and/or death due to complications; the common initial lesion leading to amputation is a nonhealing skin ulcer, induced by ulcers. Other potential applications for TRC's Gene Activated Matrix[TM] (GAM) technology include therapeutic angiogenesis (cardiovascular ischemia, peripheral arterial disease) and orthopedic products, including hard tissue (bone) and soft tissue (ligament, tendon, cartilage) repair. For more information about Cardium's Tissue Repair Company subsidiary, please visit www.t-r-co.com. Forward-Looking Statements Except for statements of historical fact, the matters discussed in this press release are forward looking and reflect numerous assumptions and involve a variety of risks and uncertainties, many of which are beyond our control and may cause actual results to differ materially from stated expectations. Actual results may also differ substantially from those described in or contemplated by this press release due to risks and uncertainties that exist in our operations and business environment, including, without limitation, risks and uncertainties that are inherent in the development of complex biologics and the conduct of human clinical trials, including the timing, costs and outcomes of such trials, our limited experience in the development, testing and marketing of therapeutic hypothermia devices and whether our efforts to accelerate the commercialization of such devices will be successful, our dependence upon proprietary technology, our history of operating losses and accumulated deficits, our reliance on collaborative relationships and critical personnel, and current and future competition, as well as other risks described from time to time in filings we make with the Securities and Exchange Commission. We undertake no obligation to release publicly the results of any revisions to these forward-looking statements to reflect events or circumstances arising after the date hereof. Copyright 2007 Cardium Therapeutics, Inc. All rights reserved. For Terms of Use Terms of Use are rules set up by the owner of an intellectual property or service to govern how they may be legally used. In many cases, terms of service are used as a contractual agreement between a company and users of a service they provide. Privacy Policy, please visit www.cardiumthx.com. Cardium Therapeutics[TM] and Generx[TM] are trademarks of Cardium Therapeutics, Inc. Gene Activated Matrix[TM] and GAM[TM] are trademarks of Tissue Repair Company. InnerCool Therapies[R], InnerCool[R] and Celsius Control System[TM] are trademarks of InnerCool Therapies, Inc. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion